poisar

Stocks · News reference

Roche's Enicepatide Meets Both Primary Endpoints In Phase II Trial, Delivering Dose-Dependent Glucose And Weight Reductions In Type 2 Diabetes And Obesity Patients

Benzinga Newsdesk

At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic controlIn patients with poor baseline glycemic control (HbA1c

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RHHBFRHHBYRHHVF
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Newsdesk

    Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks

    – Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –– IgAN is a progressive kidney disease that is

    IONSRHHBFRHHBY
  5. Delveinsight

    Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

    The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.

    ABBVJNJPFENVSRHHBY
  6. Na

    Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics

    Atavistik Bio entered into a strategic research collaboration with Roche to discover and develop novel small molecule therapeutics for cardiovascular, renal, and metabolic diseases using Atavistik's proprietary AMPS platform. Atavistik will receive $70 million upfront with potential milestone payments up to $1.9 billion plus tiered royalties, while Roche will handle preclinical and clinical development, regulatory, and commercialization activities.

    RHHBY